Innovative Medicine, Win-Win Future – KFBIO and AstraZeneca Signed – Strategic Cooperation Agreement on Onco

By Published On: 11/16/2023

On November 7, 2023, at the 6th China International Import Expo, KFBIO and AstraZeneca signed a strategic cooperation agreement on oncology digital pathology, in which the two parties will work together to promote the digital transformation of oncology pathology diagnosis and treatment, and to provide Chinese oncology patients with more accurate di

Highlights

Ms.Xie Qiong, Vice President of AstraZeneca China, and Mr.Xie Juyuan, Deputy General Manager of KFBIO, signed on behalf of both parties

El resto de este artículo se presenta en inglés para conservar el contenido técnico original.

 

KFBIO is a high-tech enterprise focusing on the field of pathology, with a leading digital pathology and pathology artificial intelligence research and development platform, the two sides will integrate their respective advantageous resources, and jointly explore the clinical application of digital pathology in the field of tumor diagnosis and treatment and academic research, to provide more accurate diagnosis and treatment solutions for Chinese tumor patients.

Mr. Xie Juyuan, Deputy General Manager of KFBIO, delivered a speech at the signing ceremony

 

This cooperation not only reflects the complementary advantages of the two sides in terms of technology and resources, but also injects new impetus into the digital transformation and upgrading of tumor pathology diagnosis and treatment, contributing to the realization of individualized precision diagnosis and treatment, and jointly assisting the realization of the goal of Healthy China 2030.

Learn more about KFBIO digital pathology solutions.

Written by : Kevin, Gui

Leave A Comment